Fluorescent in Situ Hybridization Probe Market Report 2025

The fluorescent in situ hybridization probe market size has grown strongly in recent years. It will grow from $1.55 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to the increasing use of cytogenetic analysis in prenatal testing, rising academic research on chromosomal abnormalities, growing application of FISH in microbial identification, expansion of government-funded genomics research, and enhanced capabilities of pathology laboratories.

The fluorescent in situ hybridization probe market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing adoption of FISH in research and diagnostics, rising demand for multiplexed probe solutions for rare disease detection, growing emphasis on automation in cytogenetic testing workflows, expanding application of FISH in liquid biopsies, and broader use in plant and animal genomics research. Major trends during this period include advancements in probe signal amplification techniques, development of nano-enabled FISH platforms, innovation in automation-compatible FISH assay kits, application of machine learning in probe design, and expansion of 3D FISH imaging technologies.

The rising adoption of personalized medicine is expected to drive growth in the fluorescent in situ hybridization (FISH) probe market in the coming years. Personalized medicine tailors healthcare and treatment plans to an individual’s genetic makeup, lifestyle, and environment. The increasing preference for health technologies that provide real-time monitoring and customized treatment plans is fueling this trend. FISH probes are essential in personalized medicine as they enable precise detection of chromosomal abnormalities, guiding therapeutic decisions based on an individual’s unique genetic profile. For example, in February 2023, the Personalized Medicine Coalition, a US-based professional membership organization, reported that 12 new personalized medicines approved in 2022 accounted for approximately 34% of all newly approved therapies, demonstrating a substantial increase from prior years. Thus, the growing adoption of personalized medicine is a key driver for the FISH probe market.

Companies in the FISH probe market are increasingly leveraging strategic collaborations to drive innovation and improve efficiency. Strategic collaborations allow organizations to combine resources, expertise, and technology to achieve shared long-term goals and gain access to new markets. For instance, in April 2025, Empire Genomics, a US-based molecular diagnostics company, partnered with BioDot, a provider of precision dispensing automation, to launch the BDot Probe Line. This line offers FISH probes pre-optimized for automated systems, enabling direct use without manual adjustments. Designed to operate seamlessly with the BioDot CellWriter S system, these probes streamline workflows, reduce technician intervention, and shorten time to results. The initial BDot Probe Panels support FISH analysis for a range of blood-related cancers, including multiple myeloma (MM), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and other hematologic conditions.

In November 2022, Biocare Medical LLC, a US-based provider of immunohistochemistry (IHC) and molecular pathology products, acquired Empire Genomics LLC. Through this acquisition, Biocare Medical aimed to strengthen its molecular diagnostics portfolio by integrating Empire Genomics’ expertise in FISH and genomic testing. Empire Genomics specializes in FISH probes and genomic solutions, enhancing Biocare Medical’s capabilities in delivering advanced molecular diagnostics.

Major players in the fluorescent in situ hybridization probe market are Thermo Fisher Scientific Inc., Abbott Laboratories, Oxford Gene Technology IP Limited, Sigma-Aldrich Co. LLC, Agilent Technologies Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Leica Biosystems Nussloch GmbH, Biocare Medical LLC, Enzo Biochem Inc., LGC Biosearch Technologies, ZytoVision GmbH, Creative Biolabs Inc., Empire Genomics LLC, MetaSystems GmbH, Abnova Corporation, Mirus Bio LLC, Genemed Biotechnologies Inc., Molecular Instruments Inc., and Cytocell Technologies Limited.

North America was the largest region in the luorescent in situ hybridization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fluorescent in situ hybridization probe market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the fluorescent in situ hybridization probe market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

A fluorescent in situ hybridization (FISH) probe is a short sequence of single-stranded DNA or RNA labeled with a fluorescent dye, designed to bind (hybridize) to a specific complementary DNA or RNA sequence within a cell or tissue sample. This method enables visualization and localization of specific genetic material in chromosomes, nuclei, or tissue sections using a fluorescence microscope.

The primary types of FISH probes include deoxyribonucleic acid (DNA) probes, ribonucleic acid (RNA) probes, and multiplex probes. DNA probes are molecules that carry the genetic instructions essential for the growth, development, functioning, and reproduction of all known living organisms and many viruses. These probes target genes and chromosomes and utilize various technologies, including single-color FISH, multiplex FISH, quantitative FISH, and others. FISH probes are applied in clinical diagnostics, research, agricultural biotechnology, pharmaceutical research, and genetic studies, serving multiple end users such as hospitals and clinics, research laboratories, pharmaceutical companies, and biotechnology firms.

The fluorescent in situ hybridization probe market research report is one of a series of new reports that provides fluorescent in situ hybridization probe market statistics, including fluorescent in situ hybridization probe industry global market size, regional shares, competitors with a fluorescent in situ hybridization probe market share, fluorescent in situ hybridization probe market segments, market trends and opportunities, and any further data you may need to thrive in the fluorescent in situ hybridization probe industry. This fluorescent in situ hybridization probe market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fluorescent in situ hybridization probe market consists of revenues earned by entities by providing services such as cancer research, genetic disease detection, and drug development. The market value includes the value of related goods sold by the service provider or included within the service offering. The fluorescent in situ hybridization (FISH) probe market also includes sales of fluorescent dyes, hybridization buffers, detection reagents, control slides, and assay kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.